Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous leishmaniasis in rhesus macaques (Macaca mulatta)

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 1, 2010, Pages 502-505

  Grimaldi Jr , G ^a   Porrozzi, R ^a   Friedrich, K ^a   Teva, A ^a   Marchevsky, R S ^b   Vieira, F ^c   Miekeley, N ^c   Paumgartten, F J R ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b Instituto de Technologia em Imunobiologicos   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY DERIVATIVE; N METHYLGLUCOMINE ANTIMONIATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; HISTOPATHOLOGY; LEISHMANIA BRAZILIENSIS; LIVER INJURY; LOW DRUG DOSE; MACACA; NONHUMAN; PRIORITY JOURNAL; SKIN LEISHMANIASIS;

EID: 73849098946     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00858-09     Document Type: Article

References (15)

1. Azeredo-Coutinho, R. B. G., S. C. F. Mendonça, H. Callahan, A. C. Portal, and M. Grögl. 2007. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (Glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. J. Parasitol. 93:688-693.
2. Berman, J. D. 1988. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev. Infect. Dis. 10:560-586.
3. Chulay, J. D., L. Fleckenstein, and D. H. Smith. 1988. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:69-72.
4. Croft, S. L., and G. H. Coombs. 2003. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19:502-508.
5. Cruz, A., P. M. Rainey, B. L. Herwaldt, G. Stagni, R. Palacios, R. Trujillo, and N. G. Saravia. 2007. Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate. J. Infect. Dis. 195:602-608.
6. Cupolillo, E., L. R. Brahim, C. B. Toaldo, M. P. Oliveira-Neto, M. E. F. de Brito, A. Falqueto, M. F. Naiff, and G. Grimaldi, Jr. 2003. Genetic polymorphism and molecular epidemiology of Leishmania (Viannia) braziliensis from different hosts and geographic areas in Brazil. J. Clin. Microbiol. 41:3126-3132.
7. Grimaldi, G., Jr. 2008. The utility of rhesus monkey (Macaca mulatta) and other non-human primate models for preclinical testing of Leishmania candidate vaccines-a review. Mem. Inst. Oswaldo Cruz 103:629-644.
8. Grogl, M., R. K. Martin, A. M. J. Odula, L. W. K. Milhous, and D. E. Kyle. 1991. Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components. Am. J. Trop. Med. Hyg. 45:98-111.
9. Grögl, M., A. M. J. Odula, L. D. C. Cordero, and D. E. Kyle. 1989. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:78-90.
10. Grogl, M. A., T. N. Thomason, and E. D. Franke. 1992. Drug resistance in leishmaniasis: implication in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:117-126.
11. Miekeley, N., S. R. Mortari, and A. O. Schubach. 2002. Monitoring of total antimony and its species by ICP-MS and on-line ion chromatography in biological samples from patients treated for leishmaniasis. Anal. Bioanal. Chem. 372:495-502.
12. Oliveira-Neto, M. P., A. Schubach, M. Mattos, S. C. Gonçalves-Costa, and C. Pirmez. 1997. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years). Am. J. Trop. Med. Hyg. 57:651-655.
13. Rees, P. H., M. I. Keating, P. A. Kager, and W. T. Hockmeyer. 1980. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet 2:226-229.
14. Teva, A., R. Porrozzi, E. Cupolillo, M. P. Oliveira-Neto, and G. Grimaldi, Jr. 2005. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model. J. Parasitol. 91:976-978.
15. Yardley, V., N. Ortuno, A. Llanos-Cuentas, F. Chappuis, S. D. Doncker, L. Ramirez, S. Croft. J. Arevalo, V. Adaui, H. Bermudez, S. Decuypere, and J. C. Dujardin. 2006. American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J. Infect. Dis. 194:1168-1175.